| GO ID | GO name | Interaction type | Reference |
|---|---|---|---|
| GO:0000045 | Autophagosome assembly | Increases phenotype | PMID:26610922 |
| GO:0000737 | Dna catabolic process, endonucleolytic | Increases phenotype | PMID:36138126 |
| GO:0001774 | Microglial cell activation | Increases phenotype | PMID:24299738 |
| GO:0003084 | Positive regulation of systemic arterial blood pressure | Affects phenotype | PMID:29198060 |
| GO:0005391 | P-type sodium:potassium-exchanging transporter activity | Increases phenotype | PMID:36104498 |
| GO:0006101 | Citrate metabolic process | Affects phenotype | PMID:30255327 |
| GO:0006106 | Fumarate metabolic process | Affects phenotype | PMID:30255327 |
| GO:0006108 | Malate metabolic process | Affects phenotype | PMID:30255327 |
| GO:0006117 | Acetaldehyde metabolic process | Affects phenotype | PMID:30255327 |
| GO:0006532 | Aspartate biosynthetic process | Decreases phenotype | PMID:30255327 |
| GO:0006537 | Glutamate biosynthetic process | Decreases phenotype | PMID:30255327 |
| GO:0006750 | Glutathione biosynthetic process | Increases phenotype | PMID:24101030 |
| GO:0006897 | Endocytosis | Increases phenotype | PMID:32186374 |
| GO:0006915 | Apoptotic process | Increases phenotype | PMID:29105552 |
| GO:0006919 | Activation of cysteine-type endopeptidase activity involved in apoptotic process | Increases phenotype | PMID:23820845; PMID:27255387 |
| GO:0007033 | Vacuole organization | Increases phenotype | PMID:32186374 |
| GO:0007616 | Long-term memory | Affects phenotype | PMID:24595967 |
| GO:0007626 | Locomotory behavior | Increases phenotype | PMID:25370842 |
| GO:0008219 | Cell death | Increases phenotype | PMID:24101030; PMID:26610922 |
| GO:0008283 | Cell population proliferation | Decreases phenotype | PMID:24101030; PMID:24177245 |
| GO:0009636 | Response to toxic substance | Affects phenotype | PMID:24211539 |
| GO:0010460 | Positive regulation of heart rate | Affects phenotype | PMID:29198060 |
| GO:0010635 | Regulation of mitochondrial fusion | Affects phenotype | PMID:24595818 |
| GO:0010940 | Positive regulation of necrotic cell death | Affects phenotype | PMID:23820845 |
| GO:0010942 | Positive regulation of cell death | Increases phenotype | PMID:24211539; PMID:27373168 |
| GO:0014062 | Regulation of serotonin secretion | Affects phenotype | PMID:25370842 |
| GO:0018928 | Methyl ethyl ketone metabolic process | Affects phenotype | PMID:30255327 |
| GO:0019226 | Transmission of nerve impulse | Affects phenotype | PMID:28167133 |
| GO:0019896 | Axonal transport of mitochondrion | Decreases phenotype | PMID:24595818 |
| GO:0021846 | Cell proliferation in forebrain | Decreases phenotype | PMID:27373168 |
| GO:0031650 | Regulation of heat generation | Affects phenotype | PMID:24595820 |
| GO:0031652 | Positive regulation of heat generation | Increases phenotype | PMID:25370842; PMID:30923810 |
| GO:0035641 | Locomotory exploration behavior | Affects phenotype | PMID:24595820 |
| GO:0042310 | Vasoconstriction | Increases phenotype | PMID:27079619; PMID:30448555 |
| GO:0043005 | Neuron projection | Decreases phenotype | PMID:26610922 |
| GO:0043065 | Positive regulation of apoptotic process | Affects phenotype | PMID:23820845 |
| GO:0044237 | Cellular metabolic process | Decreases phenotype | PMID:32186374 |
| GO:0046034 | Atp metabolic process | Affects phenotype | PMID:23820845 |
| GO:0046292 | Formaldehyde metabolic process | Affects phenotype | PMID:30255327 |
| GO:0051447 | Negative regulation of meiotic cell cycle | Decreases phenotype | PMID:28087314 |
| GO:0051464 | Positive regulation of cortisol secretion | Increases phenotype | PMID:24190587 |
| GO:0051612 | Negative regulation of serotonin uptake | Affects phenotype | PMID:24211539 |
| GO:0055074 | Calcium ion homeostasis | Affects phenotype | PMID:24101030 |
| GO:0060096 | Serotonin secretion, neurotransmission | Increases phenotype | PMID:24595820 |
| GO:0070994 | Detection of oxidative stress | Increases phenotype | PMID:36138126 |
| GO:0071419 | Cellular response to amphetamine | Increases phenotype | PMID:23820845 |
| GO:0072593 | Reactive oxygen species metabolic process | Increases phenotype | PMID:24101030 |
| GO:0090140 | Regulation of mitochondrial fission | Affects phenotype | PMID:24595818 |
| GO:1900535 | Palmitic acid biosynthetic process | Increases phenotype | PMID:30255327 |
| GO:1901216 | Positive regulation of neuron death | Increases phenotype | PMID:27773601 |
| GO:1903189 | Glyoxal metabolic process | Affects phenotype | PMID:30255327 |
| GO:1903296 | Positive regulation of glutamate secretion, neurotransmission | Increases phenotype | PMID:27773601 |
| GO:1990138 | Neuron projection extension | Decreases phenotype | PMID:32186374 |
| GO:2000987 | Positive regulation of behavioral fear response | Increases phenotype | PMID:24190587 |
| GO:2001025 | Positive regulation of response to drug | Increases phenotype | PMID:27773601 |
| GO:2001057 | Reactive nitrogen species metabolic process | Increases phenotype | PMID:27255387 |
We have built a comprehensive resource which compiles potential endocrine disrupting chemicals (EDCs) based on the observed adverse effects or endocrine-mediated endpoints in published experiments on humans or rodents to support basic research. We are not responsible for any errors or omissions in the published research articles or supporting literature on potential EDCs compiled in this resource. Users are advised to exercise their own judgement on the weight of evidence for potential EDCs compiled in this resource. Importantly, our sole goal to build this resource on potential EDCs is to enable future basic research towards better understanding of the systems-level perturbations upon chemical exposure rather than influencing regulatory advice on chemical use.